Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03606408 · ClinicalTrials.gov registry record · Phase 2
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
A Phase 2 study, sponsored by Recordati Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT03606408 is a Phase 2 study that has completed, run by Recordati Group. The registered enrollment target is 127 participants.
The verdict
NCT03606408, a Phase 2 study, has completed, sponsored by Recordati Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.
Interventions
- DRUG osilodrostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2023-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03606408
The ClinicalTrials.gov registry entry for NCT03606408 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recordati Group, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which osilodrostat is the first listed.
NCT03606408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03606408 about?
NCT03606408 is a clinical study titled "Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699". The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.
What is the current status of trial NCT03606408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2018-10-05. Estimated completion is 2023-11-16.
What interventions are being tested in trial NCT03606408?
The interventions under investigation include: osilodrostat (DRUG).
Who is sponsoring clinical trial NCT03606408?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.